[go: up one dir, main page]

ATE544471T1 - Zusammensetzung mit iscom-teilchen und lebenden mikroorganismen - Google Patents

Zusammensetzung mit iscom-teilchen und lebenden mikroorganismen

Info

Publication number
ATE544471T1
ATE544471T1 AT04723123T AT04723123T ATE544471T1 AT E544471 T1 ATE544471 T1 AT E544471T1 AT 04723123 T AT04723123 T AT 04723123T AT 04723123 T AT04723123 T AT 04723123T AT E544471 T1 ATE544471 T1 AT E544471T1
Authority
AT
Austria
Prior art keywords
composition
organisms
iscom
living microorganisms
micro
Prior art date
Application number
AT04723123T
Other languages
English (en)
Inventor
Bror Morein
Bengtsson Karin Loevgren
Original Assignee
Isconova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20290755&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE544471(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isconova Ab filed Critical Isconova Ab
Application granted granted Critical
Publication of ATE544471T1 publication Critical patent/ATE544471T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04723123T 2003-03-24 2004-03-24 Zusammensetzung mit iscom-teilchen und lebenden mikroorganismen ATE544471T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300795A SE0300795D0 (sv) 2003-03-24 2003-03-24 Composition comprising iscom particles and live micro-organisms
PCT/SE2004/000451 WO2004084941A1 (en) 2003-03-24 2004-03-24 Composition comprising iscom particles and live micro-organisms

Publications (1)

Publication Number Publication Date
ATE544471T1 true ATE544471T1 (de) 2012-02-15

Family

ID=20290755

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04723123T ATE544471T1 (de) 2003-03-24 2004-03-24 Zusammensetzung mit iscom-teilchen und lebenden mikroorganismen

Country Status (11)

Country Link
US (5) US7838019B2 (de)
EP (1) EP1635867B1 (de)
AT (1) ATE544471T1 (de)
AU (1) AU2004224487B2 (de)
BR (1) BRPI0408587A (de)
CA (1) CA2519806C (de)
ES (1) ES2379351T3 (de)
NZ (1) NZ542328A (de)
SE (1) SE0300795D0 (de)
WO (1) WO2004084941A1 (de)
ZA (1) ZA200506988B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0300795D0 (sv) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
DK1838341T3 (da) 2005-01-20 2013-11-04 Isconova Ab Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
WO2011005183A1 (en) * 2009-07-10 2011-01-13 Isconova Ab New composition
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
US10751410B2 (en) * 2013-09-19 2020-08-25 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (MERS-CoV) compositions and methods
EP3117831A1 (de) 2015-07-16 2017-01-18 Nuritas Limited Peptide zur verwendung bei der förderung des glucosetransports in skelettmuskeln
EP3117830A1 (de) 2015-07-16 2017-01-18 Nuritas Limited Antibakterielle peptide und verwendungen davon
KR102307260B1 (ko) 2015-07-16 2021-10-01 뉴리타스 리미티드 항염증 펩티드, 및 그의 용도
EP3118216A1 (de) 2015-07-16 2017-01-18 Nuritas Limited Zellwachstum und proliferation fördernde peptide und verwendungen davon
EP3118215A1 (de) 2015-07-16 2017-01-18 Nuritas Limited Entzündungshemmende peptide und verwendungen davon
WO2018014936A1 (en) 2016-07-18 2018-01-25 Nuritas Limited Topical compositions
EP3329905A1 (de) 2016-12-05 2018-06-06 Nuritas Limited Topische kosmetische zusammensetzungen enhaltend ein oligopeptid gegen die hautalterung
CN110381976A (zh) 2016-12-05 2019-10-25 努里塔斯有限公司 包括肽wkdeagkplvk的组合物
WO2019238962A1 (en) 2018-06-14 2019-12-19 University College Cork - National University Of Ireland, Cork Peptide for disease treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0231039B1 (de) * 1986-01-14 1992-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Verfahren zur Herstellung immunologischer Komplexe und diese enthaltende pharmazeutische Zusammensetzung
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
GB8919819D0 (en) 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
NL9002314A (nl) 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
GB9320668D0 (en) * 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
AU1991095A (en) * 1994-03-09 1995-09-25 Pacific Biotech International, Inc. Activating virus
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5676354A (en) * 1995-07-14 1997-10-14 Fuji Photo Film Co., Ltd. Sheet film pack
US5753235A (en) * 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
PT835930E (pt) * 1996-10-09 2001-06-29 Akzo Nobel Nv Estirpes europeias de vacina do virus do sindroma reprodutivo e respiratorio porcino (prrsv)
WO2004030696A2 (en) * 2002-10-02 2004-04-15 Nordic Vaccine Technology A/S Composition for vaccination
SE0300795D0 (sv) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms

Also Published As

Publication number Publication date
US9901634B2 (en) 2018-02-27
EP1635867B1 (de) 2012-02-08
US9205147B2 (en) 2015-12-08
AU2004224487B2 (en) 2009-08-06
EP1635867A1 (de) 2006-03-22
CA2519806A1 (en) 2004-10-07
US20200323979A9 (en) 2020-10-15
US20140120131A1 (en) 2014-05-01
US20110081378A1 (en) 2011-04-07
ES2379351T3 (es) 2012-04-25
BRPI0408587A (pt) 2006-03-21
WO2004084941A1 (en) 2004-10-07
NZ542328A (en) 2009-10-30
US20180369369A1 (en) 2018-12-27
SE0300795D0 (sv) 2003-03-24
US10813994B2 (en) 2020-10-27
US20080095795A1 (en) 2008-04-24
US20160114034A1 (en) 2016-04-28
AU2004224487A1 (en) 2004-10-07
US7838019B2 (en) 2010-11-23
CA2519806C (en) 2012-06-19
ZA200506988B (en) 2006-07-26

Similar Documents

Publication Publication Date Title
ATE544471T1 (de) Zusammensetzung mit iscom-teilchen und lebenden mikroorganismen
MX2007010045A (es) Pirazolopirimidinas.
PL2018441T3 (pl) Mikroorganizmy znakowane i sposoby znakowania
SG155947A1 (en) Compositions and methods for the diagnosis and treatment of tumor
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
IL175520A0 (en) Method for the cultivation of microorganisms of the genus thraustochytriales by using an optimized low salt medium
SI1869161T1 (sl) Postopek za pripravo nealergijskih probiotičnih bakterijskih kultur in ustrezna uporaba
MX336500B (es) Insecticida para uso agricola u horticola y metodo para su uso.
BRPI0417823A (pt) métodos para uso de bifidobactérias probióticas para animais de estimação
UA105778C2 (uk) Піразол-4-n-алкоксикарбоксаміди як мікробіоциди, композиція, що їх містить, та спосіб боротьби із зараженням корисних рослин фітопагенними мікроорганізмами або його попередження з їх використанням
EP1670450B8 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
BRPI0417825A (pt) métodos para uso de lactobacilli probióticos para animais de estimação
ZA200803819B (en) Probiotic Enterococci for improved immunity
ECSP055725A (es) Formulaciones nutricionales que contienen sustancias simbióticas
ATE454463T1 (de) Überexpression von extremozymgenen in pseudomonas und nahe verwandte bakterien
BRPI0413002A (pt) genes de ciclo de célula de planta e métodos de uso
WO2007053731A3 (en) Expression of soluble factor viii proteins in bacteria
MX2010002867A (es) Cepas de micoplasma atenuadas vivas.
ATE354964T1 (de) Probiotische zusammensetzung mit mindestens zwei milchsäurebakterienstämmen, die zur kolonisierung des magen-darm-trakts fähig sind und in kombination damit die eigenschaften, im darm zu überleben, an den darm zu binden, gegen infektion zu schützen und ballaststoffe zu fermentieren, aufweisen
MX2007007288A (es) Desacilacion de lps en bacterias gram negativas.
ATE439851T1 (de) Verwendung probiotischer bakterien zur behandlung von infektionen
EA200600021A1 (ru) Пиразолопиримидины
DE60317165D1 (de) Bakterielle autolysate
DE60227837D1 (de) Isolierung und kultivierung von mikroorganismen aus natürlichen umgebungen und darauf beruhende entdeckung von arzneistoffen
WO2007005659A3 (en) Methods and compositions for culturing keratinocytes